Trial reportPloS one2021
Seroprevalence of SARS-CoV-2 antibodies among homeless people living rough, in shelters and squats: A large population-based study in France.
Trial report in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- A systematic review of the international evidence on the effectiveness of COVID-19 mitigation measures in communal rough sleeping accommodation.Journal of public health (Oxford, England) · 2023Pooled it
- The Impact of Being Homeless on the Clinical Outcomes of COVID-19: Systematic Review.International journal of public health · 2023Pooled it
- SARS-CoV-2 incidence, seroprevalence, and COVID-19 vaccination coverage in the homeless population: a systematic review and meta-analysis.Frontiers in public health · 2023Pooled it
- Article
- Article
- Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies.Harm reduction journal · 2024Article
- [Health of homeless individuals during the COVID-19 pandemic].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2023Review
- High SARS-CoV-2 seroprevalence among street adolescents in Lomé, Togo, 2021.BMC infectious diseases · 2023Article
- Incidence of SARS-CoV-2 Infection Among People Experiencing Homelessness in Toronto, Canada.JAMA network open · 2023Article
- Cumulative incidence of SARS-CoV-2 infection within the homeless population: insights from a city-wide longitudinal study.BMJ open · 2023Article
- Estimating COVID-19 vaccine uptake and its drivers among migrants, homeless and precariously housed people in France.Communications medicine · 2023Article
- Morbidity and mortality in a prospective cohort of people who were homeless during the COVID-19 pandemic.Frontiers in public health · 2023Observational
- Article
- Race and Ethnicity and Sex Variation in COVID-19 Mortality Risks Among Adults Experiencing Homelessness in Los Angeles County, California.JAMA network open · 2022Article
- Salivary Antibody Response of COVID-19 in Vaccinated and Unvaccinated Young Adult Populations.Vaccines · 2022Article
- COVID-19 prevalence and infection control measures at homeless shelters and hostels in high-income countries: a scoping review.Systematic reviews · 2022Article
- Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Associates With Unstable Housing and Occurs in the Presence of Antibodies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- A Scoping Review of the Health Impact of the COVID-19 Pandemic on Persons Experiencing Homelessness in North America and Europe.International journal of environmental research and public health · 2022Article
- Residential Mobility of a Cohort of Homeless People in Times of Crisis: COVID-19 Pandemic in a European Metropolis.International journal of environmental research and public health · 2022Article
- "Locked down outside": Perception of hazard and health resources in COVID-19 epidemic context among homeless people.SSM - population health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvercrowded housing, as well as inadequate sanitary conditions, contribute to making homeless people particularly vulnerable to the SARS-CoV-2 infection. We aimed to assess the seroprevalence of the SARS-CoV-2 infection among people experiencing homelessness on a large city-wide scale in Marseille, France, taking into account different types of accommodation.
methodsA consortium of outreach teams in 48 different locations including streets, slums, squats, emergency or transitional shelters and drop-in centres participated in the inclusion process. All participants consented to have a validated rapid antibody assay for immunoglobulins M (IgM) and G (IgG) and to answer a questionnaire on medical health conditions, comorbidities, and previous COVID-19 symptoms. Information on their housing conditions since the COVID-19 crisis was also collected from the participants.
resultsFrom June 01 to August 05, 2020, 1,156 homeless participants were enrolled in the study and tested. The overall seroprevalence of SARS-CoV-2 IgG/IgM antibodies was 5.6% (95%CI 2.3-7.0), ranging from 2.2% in people living on the streets to 8.1% in people living in emergency shelters (P = 0.009). Around one third of the seropositive participants reported COVID-19 symptoms. Compared to the general population in Marseille (3.6%), the homeless population living in the same urban area experienced a significantly increased risk of SARS-CoV-2 infection (|z| = 3.65 > 1.96).
conclusionThese findings highlight the need for regular screening among the homeless to prevent clustering in overcrowded or inadequate accommodations. It is also necessary to provide essential resources to keep homeless people healthy, the vast majority of whom have cumulative risk factors for SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.